Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.

In a report released today, David Dai from UBS maintained a Buy rating on Kura Oncology, with a price target of $15.00. According to TipRanks, Dai ...

UBS Remains a Buy on Kura Oncology (KURA)

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology yesterday and set a price target of $31.00. The company’...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KURA	$12.66	-3.95%	1.81M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KURA	$12.66	-3.9%	1.81M
3
4
5
6

KURA

Get Kura Oncology, Inc. Data in Excel

Get Kura Oncology, Inc. Data in Excel